Reuters logo
BRIEF-Karyopharm reports Q4 loss of $0.65 per share
March 16, 2017 / 11:51 AM / in 7 months

BRIEF-Karyopharm reports Q4 loss of $0.65 per share

March 16 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm reports fourth quarter and full year 2016 financial results and provides Selinexor clinical update

* For quarter, research and development expense was $20.7 million compared to $24.1 million for quarter ended December 31, 2015

* Net loss $0.65 per share for quarter ended December 31, 2016

* Expects operating cash burn for year ending December 31, 2017 to be in range of $85 to 90 million

* Says expects to commence Boston study in early 2017

* Expects that existing cash and cash equivalents will fund its research and development programs and operations until end of 2018

* SDD ARM of Stomp study expected to enroll about 44 patients and Co expects to report top-line data in late 2017 or early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below